InstalabLoading...
InstalabLoading...
If you have your DHA (docosahexaenoic acid) level measured, you are looking at how much of a specific omega-3 fat is circulating in your blood. Unlike a general omega-3 test, DHA tells you something particular: whether your body has enough of the fatty acid it relies on most heavily for brain structure, and whether that level is in a range associated with lower risk of dying from heart disease or cancer.
DHA is not interchangeable with EPA, the other major omega-3 you will see on lab reports. They behave differently in your body. DHA is the dominant omega-3 in your brain, making up roughly 40% of the polyunsaturated fats in the membranes of your neurons. EPA plays a more peripheral role. On the lipid side, DHA lowers triglycerides more effectively than EPA but also raises LDL cholesterol, something EPA does not do. Understanding your DHA level separately from EPA helps you make sharper decisions about supplementation.
Large observational studies consistently link higher DHA levels to longer life. In a study of nearly 118,000 adults followed for about 13 years, those with the highest DHA levels had roughly a 21% lower risk of dying from any cause compared to those with the lowest levels. When that data was pooled with 17 other prospective studies covering more than 160,000 people total, higher DHA was associated with about 17% lower risk of dying from any cause, 21% lower cardiovascular mortality, and 17% lower cancer mortality.
Those are meaningful numbers. But observational data cannot prove that raising your DHA level causes those benefits. It is possible that people with higher DHA eat better overall, exercise more, or differ in other ways. That is where intervention trials come in, and the picture gets more complicated.
Combined EPA and DHA supplements do reduce heart attacks and coronary events in meta-analyses of randomized trials. But when researchers have tried to tease apart which omega-3 deserves the credit, EPA comes out ahead. The largest positive trial, REDUCE-IT, used EPA alone and showed striking cardiovascular benefits. By contrast, a secondary analysis of the STRENGTH trial found that even when people achieved high blood levels of DHA (above 105 micrograms per milliliter), there was no association with fewer cardiovascular events (HR 1.02), even among those who also reached EPA levels comparable to those in REDUCE-IT.
This does not mean DHA is useless for your heart. It means the strongest trial evidence for preventing heart attacks currently favors EPA. DHA may contribute through other pathways, like lowering triglycerides or reducing inflammation, without showing up as a clear winner in event-driven trials.
One risk worth knowing about: high-dose omega-3 supplements, whether EPA alone or EPA plus DHA, are associated with a higher rate of new-onset atrial fibrillation, an irregular heart rhythm. If you have a history of atrial fibrillation or are at elevated risk, discuss high-dose supplementation with a clinician before starting.
Your brain is unusually hungry for DHA. It is preferentially pulled into the developing brain during pregnancy and the first two years of life, where it supports the growth of new neurons, the flexibility of connections between them, and protective mechanisms against cell damage.
For pregnant and breastfeeding women, maternal DHA intake directly shapes infant brain development. A pooled analysis of 8 trials estimated that each additional 100 mg per day of maternal DHA was associated with about a 0.13-point increase in the child's IQ. A meta-analysis of 14 trials found that DHA supplementation improved infant visual acuity in a dose-dependent way. And a separate review of 21 studies found that DHA supplementation in infants significantly improved scores on a standard measure of motor development.
The long-term picture is less clear. One well-designed trial gave pregnant women 600 mg of DHA daily and followed the children through age 6. Prenatal DHA reduced early preterm birth and improved visual attention in infancy, but did not produce consistent cognitive advantages years later.
In adults, the story depends on where you are cognitively. Prospective studies suggest that higher fish or DHA intake is associated with reduced risk of mild cognitive decline and Alzheimer's disease. In one study, cognitively healthy adults with coronary artery disease who took about 3.4 grams of combined EPA and DHA daily experienced cognitive aging that was slowed by roughly 2.5 years. DHA supplementation has shown benefit in people with mild cognitive impairment but not in those with established Alzheimer's disease. Among 15 randomized trials in cognitively healthy older adults, about half showed benefit and half did not, with differences likely related to dose, duration, genetic background, and starting cognitive status.
What this means for you: DHA appears most protective for your brain before significant decline has set in. If you have early memory concerns, a family history of dementia, or carry the apolipoprotein E4 gene variant (a known Alzheimer's risk factor), there is reasonable evidence to support DHA supplementation sooner rather than later.
Your circulating DHA level is primarily driven by how much you consume, since your body converts very little DHA from plant-based omega-3 sources like flaxseed.
Dietary intake: Fatty fish (salmon, mackerel, sardines, anchovies) is the most concentrated food source of DHA. Two or more servings per week typically supplies the general recommendation of 250 to 500 mg per day of combined EPA and DHA. If you do not eat fish, algae-based DHA supplements provide the same molecule without the fish.
Supplementation for triglyceride lowering: Higher doses of 2 to 4 grams per day are used to reduce elevated triglycerides. In a head-to-head randomized crossover trial of 154 adults with abdominal obesity, 2.7 grams per day of DHA reduced triglycerides by 13.3%, compared to 11.9% for the same dose of EPA. DHA also raised HDL cholesterol by 7.6%, while EPA had essentially no effect on HDL.
The LDL trade-off: DHA raises LDL cholesterol, while EPA tends to lower it or leave it unchanged. This is confirmed across multiple meta-analyses of randomized trials. If your LDL is already high or you have severe dyslipidemia, an EPA-predominant supplement may be a better choice. This is a decision worth discussing with your clinician.
Anti-inflammatory effects: Both EPA and DHA reduce C-reactive protein (CRP), a general marker of inflammation, with effects strongest in people who have dyslipidemia and elevated CRP at baseline. DHA may have an edge on certain inflammatory markers: in the head-to-head trial, DHA reduced IL-18 (an inflammatory signaling molecule) by 7.0%, while EPA showed almost no change. DHA also increased adiponectin, a hormone linked to better metabolic health, by 3.1%, while EPA slightly decreased it. Supplements with a lower EPA-to-DHA ratio appear to be more effective at reducing overall inflammation.